Press Releases Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
5.17 ^USD	-3.54%		+5.94%	+33.94%

May. 23	Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting	CI
May. 03	Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors	Jun. 01	AQ
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference	May. 30	AQ
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting	May. 23	AQ
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	May. 03	AQ
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 24	AQ
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting	Apr. 23	AQ
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting	Apr. 05	AQ
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting	Apr. 04	AQ
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 07	AQ
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference	Mar. 06	AQ
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024	Mar. 05	AQ
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook	Jan. 08	AQ
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors	Jan. 04	AQ
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference	Nov. 22	AQ
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 14	AQ
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	Nov. 03	AQ
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	23-10-31	AQ
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	23-09-27	AQ
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124	23-09-11	AQ
Werewolf Therapeutics to Participate in Upcoming Investor Conferences	23-09-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Press Releases

Filters